8-K Announcements
6Material company update
Feb 26, 2026·SEC
Material company update
Nov 13, 2025·SEC
Material company update
Oct 27, 2025·SEC
Fate Therapeutics, Inc.(FATE)Earnings, Financials & Key Ratios
FATE•NASDAQ
$2.29
$264M mkt cap·Price updated May 6, 2026
AboutFate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.Show more
- Revenue$7M-51.2%
- EBITDA-$148M+22.8%
- Net Income-$136M+26.8%
- EPS (Diluted)-1.15+29.9%
- EBITDA Margin-2222.45%-58.3%
- Operating Margin-2222.45%-44.1%
- Net Margin-2051.08%-50.1%
- ROE-51.84%+4.4%
- ROIC-36.54%+7.6%
- Debt/Equity0.38+40.5%
FATE Key Insights
Fate Therapeutics, Inc. (FATE) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading near 52-week high
- ✓Trading at only 1.3x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Sales declining 26.7% over 5 years
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
FATE Price & Volume
Fate Therapeutics, Inc. (FATE) stock price & volume — 10-year historical chart
Loading chart...
FATE Growth Metrics
Fate Therapeutics, Inc. (FATE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years10.58%
5 Years-26.71%
3 Years-58.98%
TTM-51.24%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM26.82%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM29.88%
Return on Capital
10 Years-42.13%
5 Years-40.42%
3 Years-42.5%
Last Year-43.12%
FATE Recent Earnings
Fate Therapeutics, Inc. (FATE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 11/12 qtrs (92%)
Q1 2026Latest
Feb 26, 2026EPS
$0.27
Est $0.27
+0.0%
Revenue
$1M
Est $1M
+2.4%
Q4 2025
Nov 13, 2025EPS
$0.27
Est $0.29
+6.9%
Revenue
$2M
Est $1M
+45.3%
Q3 2025
Aug 12, 2025EPS
$0.29
Est $0.35
+17.1%
Revenue
$2M
Est $1M
+66.0%
Q2 2025
May 13, 2025EPS
$0.32
Est $0.39
+17.9%
Revenue
$2M
Est $1M
+37.5%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 26, 2026 | $0.27vs $0.27+0.0% | $1Mvs $1M+2.4% |
| Q4 2025 | Nov 13, 2025 | $0.27vs $0.29+6.9% | $2Mvs $1M+45.3% |
| Q3 2025 | Aug 12, 2025 | $0.29vs $0.35+17.1% | $2Mvs $1M+66.0% |
| Q2 2025 | May 13, 2025 | $0.32vs $0.39+17.9% | $2Mvs $1M+37.5% |
Based on last 12 quarters of dataView full earnings history →
FATE Peer Comparison
Fate Therapeutics, Inc. (FATE) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CRSP | 5.31B | 55.08 | -8.51 | -89.97% | -138.57% | -30.88% | 0.21 | |
 NTLA | 1.61B | 13.85 | -3.64 | -100% | -61.47% | 0.14 | ||
 BEAM | 3.32B | 32.33 | -39.92 | 120.01% | -57.24% | -7.31% | 0.24 | |
 EDIT | 310.73M | 3.18 | -1.76 | -100% | -5.23% | 0.66 | ||
 SANA | 954.64M | 3.64 | -3.14 | -120.02% | 0.38 | |||
 ALNY | 40.43B | 303.00 | 130.04 | 65.19% | 13.46% | 98.29% | 1.62 | |
 KYMR | 7.04B | 86.26 | -23.38 | -16.72% | -6.12% | -25.02% | 0.05 | |
 CELC | 6.03B | 139.44 | -49.27 | -179% | 0.85 |
Compare FATE vs Peers
Fate Therapeutics, Inc. (FATE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
FATE Income Statement
Fate Therapeutics, Inc. (FATE) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 4.11M | 4.74M | 10.68M | 31.43M | 55.85M | 96.3M | 63.53M | 13.63M | 6.65M |
| Revenue Growth % | -6.72% | 15.44% | 125.32% | 194.33% | 77.66% | 72.44% | -34.03% | -78.55% | -51.24% |
| Cost of Goods Sold | 34.36M | 56.02M | 0 | 125.62M | 5.85M | 13.76M | 157.19M | 0 | 0 |
| COGS % of Revenue | 836.78% | 1181.94% | - | 399.64% | 10.48% | 14.29% | 247.41% | - | - |
| Gross Profit | -30.25M▲ 0% | -51.28M▼ 69.5% | 10.68M▲ 120.8% | -94.19M▼ 981.9% | 50M▲ 153.1% | 82.54M▲ 65.1% | -93.65M▼ 213.5% | 13.63M▲ 114.6% | 0▼ 100.0% |
| Gross Margin % | -736.78% | -1081.94% | 100% | -299.64% | 89.52% | 85.71% | -147.41% | 100% | - |
| Gross Profit Growth % | -37.2% | -69.52% | 120.83% | -981.92% | 153.08% | 65.1% | -213.46% | 114.55% | -100% |
| Operating Expenses | 46.23M | 71.83M | 111.41M | 33.9M | 266.99M | 390.93M | 96.86M | 223.91M | 154.35M |
| OpEx % of Revenue | 1125.94% | 1515.44% | 1043.14% | 107.83% | 478.08% | 405.95% | 152.45% | 1642.63% | 2322.45% |
| Selling, General & Admin | 11.87M | 15.81M | 23.64M | 33.9M | 57.32M | 84.23M | 96.86M | 74.17M | 46.52M |
| SG&A % of Revenue | 289.16% | 333.5% | 221.32% | 107.83% | 102.64% | 87.47% | 152.45% | 544.12% | 699.99% |
| Research & Development | 34.36M | 56.02M | 87.77M | 125.62M | 215.52M | 320.45M | 172.6M | 135M | 107.83M |
| R&D % of Revenue | 836.78% | 1181.94% | 821.82% | 399.64% | 385.92% | 332.77% | 271.66% | 990.4% | 1622.46% |
| Other Operating Expenses | 0 | 0 | 0 | -125.62M | -5.85M | -13.76M | -172.6M | 14.74M | 0 |
| Operating Income | -42.13M▲ 0% | -67.09M▼ 59.3% | -100.73M▼ 50.1% | -128.09M▼ 27.2% | -216.99M▼ 69.4% | -308.39M▼ 42.1% | -190.51M▲ 38.2% | -210.28M▼ 10.4% | -147.7M▲ 29.8% |
| Operating Margin % | -1025.94% | -1415.44% | -943.14% | -407.47% | -388.56% | -320.23% | -299.86% | -1542.63% | -2222.45% |
| Operating Income Growth % | -31.79% | -59.27% | -50.13% | -27.16% | -69.41% | -42.12% | 38.22% | -10.37% | 29.76% |
| EBITDA | -41.15M | -65.89M | -98.53M | -125M | -211.14M | -294.63M | -172.23M | -191.31M | -147.7M |
| EBITDA Margin % | -1002.29% | -1390.04% | -922.6% | -397.65% | -378.08% | -305.95% | -271.09% | -1403.52% | -2222.45% |
| EBITDA Growth % | -32.4% | -60.1% | -49.55% | -26.86% | -68.92% | -39.54% | 41.54% | -11.08% | 22.8% |
| D&A (Non-Cash Add-back) | 971K | 1.2M | 2.19M | 3.09M | 5.85M | 13.76M | 18.28M | 18.96M | 0 |
| EBIT | -41.68M | -64.9M | -96.4M | -128.09M | -216.99M | -308.39M | -190.51M | -195.54M | 0 |
| Net Interest Income | -709K | 494K | 2.58M | 2.4M | 1.31M | 5.84M | 17.19M | 17.29M | 0 |
| Interest Income | 559K | 2.19M | 4.33M | 2.4M | 1.31M | 5.84M | 17.19M | 17.29M | 11.05M |
| Interest Expense | 1.27M | 1.7M | 1.75M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -827K | 494K | 2.58M | -45.3M | 4.84M | 26.66M | 29.58M | 24.01M | 11.39M |
| Pretax Income | -42.95M▲ 0% | -66.6M▼ 55.1% | -98.15M▼ 47.4% | -173.39M▼ 76.7% | -212.15M▼ 22.4% | -281.72M▼ 32.8% | -160.93M▲ 42.9% | -186.26M▼ 15.7% | -136.31M▲ 26.8% |
| Pretax Margin % | -1046.08% | -1405.02% | -919% | -551.59% | -379.89% | -292.55% | -253.3% | -1366.46% | -2051.08% |
| Income Tax | 297K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | -0.69% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -42.95M▲ 0% | -66.6M▼ 55.1% | -98.15M▼ 47.4% | -173.39M▼ 76.7% | -212.15M▼ 22.4% | -281.72M▼ 32.8% | -160.93M▲ 42.9% | -186.26M▼ 15.7% | -136.31M▲ 26.8% |
| Net Margin % | -1046.08% | -1405.02% | -919% | -551.59% | -379.89% | -292.55% | -253.3% | -1366.46% | -2051.08% |
| Net Income Growth % | -28.36% | -55.05% | -47.38% | -76.66% | -22.36% | -32.79% | 42.88% | -15.74% | 26.82% |
| Net Income (Continuing) | -42.95M | -66.6M | -98.15M | -173.39M | -212.15M | -281.72M | -160.93M | -186.26M | -136.31M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.02▲ 0% | -1.19▼ 16.7% | -1.43▼ 20.2% | -2.10▼ 46.9% | -2.24▼ 6.7% | -2.91▼ 29.9% | -1.64▲ 43.6% | -1.64▲ 0.0% | -1.15▲ 29.9% |
| EPS Growth % | 2.86% | -16.67% | -20.17% | -46.85% | -6.67% | -29.91% | 43.64% | 0% | 29.88% |
| EPS (Basic) | -1.02 | -1.19 | -1.43 | -2.10 | -2.24 | -2.91 | -1.64 | -1.64 | -1.15 |
| Diluted Shares Outstanding | 41.98M | 56.2M | 68.19M | 82.39M | 94.75M | 96.83M | 98.41M | 113.69M | 118.79M |
| Basic Shares Outstanding | 41.98M | 56.2M | 68.19M | 82.39M | 94.75M | 96.83M | 98.41M | 113.69M | 118.79M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
FATE Balance Sheet
Fate Therapeutics, Inc. (FATE) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 102.6M | 205.2M | 227.09M | 494.32M | 633.41M | 502.07M | 331.54M | 291.91M | 208.7M |
| Cash & Short-Term Investments | 100.95M | 201.01M | 221.43M | 482.92M | 615.91M | 436.23M | 315.18M | 279.07M | 203.66M |
| Cash Only | 88.95M | 190.51M | 99.81M | 167.35M | 133.58M | 61.33M | 41.87M | 36.06M | 46.63M |
| Short-Term Investments | 12M | 10.49M | 121.61M | 315.57M | 482.33M | 374.89M | 273.31M | 243.01M | 157.03M |
| Accounts Receivable | 0 | 500K | 0 | 5.51M | 8.68M | 38.48M | 1.83M | 3.54M | 916K |
| Days Sales Outstanding | - | 38.5 | - | 64.04 | 56.7 | 145.85 | 10.49 | 94.76 | 50.31 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 1.65M | 0 | 5.66M | 5.89M | 0 | 27.37M | 900K | 9.3M | 4.13M |
| Total Non-Current Assets | 2.7M | 7.84M | 75.19M | 128.13M | 288.04M | 203.49M | 174.68M | 148.78M | 110.23M |
| Property, Plant & Equipment | 2.55M | 5.13M | 22.75M | 99.39M | 162.25M | 66.07M | 158.51M | 110.89M | 98.53M |
| Fixed Asset Turnover | 1.61x | 0.92x | 0.47x | 0.32x | 0.34x | 1.46x | 0.40x | 0.12x | 0.07x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 122K | 2.19M | 39.44M | 28.73M | 100.66M | 4.94M | 980K | 27.66M | 1.47M |
| Other Non-Current Assets | 24K | 526K | 12.99M | 9K | 25.13M | 132.48M | 15.19M | 10.24M | 10.23M |
| Total Assets | 105.29M▲ 0% | 213.03M▲ 102.3% | 302.27M▲ 41.9% | 622.46M▲ 105.9% | 921.46M▲ 48.0% | 705.56M▼ 23.4% | 506.22M▼ 28.3% | 440.69M▼ 12.9% | 318.94M▼ 27.6% |
| Asset Turnover | 0.04x | 0.02x | 0.04x | 0.05x | 0.06x | 0.14x | 0.13x | 0.03x | 0.02x |
| Asset Growth % | 10.78% | 102.33% | 41.89% | 105.92% | 48.04% | -23.43% | -28.25% | -12.94% | -27.63% |
| Total Current Liabilities | 11.05M | 27.26M | 27.81M | 85.56M | 81.28M | 114.05M | 39.09M | 38.52M | 36.07M |
| Accounts Payable | 1.68M | 4.21M | 5.82M | 6.28M | 8.61M | 8.27M | 4.72M | 9.37M | 2.66M |
| Days Payables Outstanding | 17.83 | 27.4 | - | 18.26 | 537.33 | 219.27 | 10.96 | - | - |
| Short-Term Debt | 0 | 2.44M | 0 | 3.35M | 0 | 0 | 0 | 0 | 4.56M |
| Deferred Revenue (Current) | 2.1M | 7.59M | 2.79M | 21.14M | 21.48M | 42.23M | 0 | 393K | 381K |
| Other Current Liabilities | 5.5M | 10.09M | 12.18M | 49.97M | 3.2M | 40.03M | 685K | 11.64M | 31.13M |
| Current Ratio | 9.29x | 7.53x | 8.17x | 5.78x | 7.79x | 4.40x | 8.48x | 7.58x | 5.79x |
| Quick Ratio | 9.29x | 7.53x | 8.17x | 5.78x | 7.79x | 4.40x | 8.48x | 7.58x | 5.79x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 17.05M | 25.3M | 29.71M | 152.45M | 161.33M | 107.57M | 98.71M | 83.45M | 75.68M |
| Long-Term Debt | 14.81M | 12.45M | 0 | 0 | 0 | 0 | 0 | 0 | 73.29M |
| Capital Lease Obligations | 0 | 0 | 25.23M | 93.94M | 109.24M | 103.71M | 97.36M | 77.85M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1.52M | 5.35M | 702K | 12.48M | 24.97M | 3.86M | 1.35M | 5.6M | 2.4M |
| Total Liabilities | 28.1M | 52.56M | 57.52M | 238.01M | 242.62M | 221.62M | 137.8M | 121.97M | 111.75M |
| Total Debt | 14.81M | 14.88M | 26.93M | 97.3M | 114.82M | 109.34M | 103.54M | 85.27M | 77.85M |
| Net Debt | -74.14M | -175.63M | -72.89M | -70.05M | -18.77M | 48.01M | 61.67M | 49.21M | 31.22M |
| Debt / Equity | 0.19x | 0.09x | 0.11x | 0.25x | 0.17x | 0.23x | 0.28x | 0.27x | 0.38x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -33.22x | -39.56x | -57.49x | - | - | - | - | - | - |
| Total Equity | 77.19M▲ 0% | 160.47M▲ 107.9% | 244.76M▲ 52.5% | 384.44M▲ 57.1% | 678.84M▲ 76.6% | 483.94M▼ 28.7% | 368.42M▼ 23.9% | 318.73M▼ 13.5% | 207.18M▼ 35.0% |
| Equity Growth % | 5.52% | 107.89% | 52.53% | 57.07% | 76.58% | -28.71% | -23.87% | -13.49% | -35% |
| Book Value per Share | 1.84 | 2.86 | 3.59 | 4.67 | 7.16 | 5.00 | 3.74 | 2.80 | 1.74 |
| Total Shareholders' Equity | 77.19M | 160.47M | 244.76M | 384.44M | 678.84M | 483.94M | 368.42M | 318.73M | 207.18M |
| Common Stock | 53K | 65K | 76K | 88K | 96K | 97K | 99K | 114K | 115K |
| Retained Earnings | -218.8M | -285.4M | -383.55M | -556.93M | -769.08M | -1.05B | -1.21B | -1.4B | -1.53B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -3K | -2K | 22K | 70K | -762K | -1.85M | 15K | 268K | 116K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
FATE Cash Flow Statement
Fate Therapeutics, Inc. (FATE) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -36.91M | -38.65M | -83.17M | -39.23M | -162.87M | -248.21M | -132.26M | -122.87M | -106.08M |
| Operating CF Margin % | -898.81% | -815.4% | -778.79% | -124.8% | -291.64% | -257.74% | -208.18% | -901.43% | -1596.21% |
| Operating CF Growth % | -23.75% | -4.73% | -115.2% | 52.84% | -315.18% | -52.4% | 46.71% | 7.1% | 13.66% |
| Net Income | -42.95M | -66.6M | -98.15M | -173.39M | -212.15M | -281.72M | -160.93M | -186.26M | -136.31M |
| Depreciation & Amortization | 971K | 1.2M | 2.19M | 3.09M | 5.85M | 13.76M | 18.28M | 18.96M | 9.29M |
| Stock-Based Compensation | 3.61M | 6.29M | 17.41M | 30.75M | 54.36M | 78.73M | 43.46M | 41.5M | 24.92M |
| Deferred Taxes | 5K | -335K | -478K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -613K | 19.04M | -7.79M | 113.09M | -13.03M | -24.27M | -52.26M | 4.89M | -3.99M |
| Working Capital Changes | 2.08M | 1.74M | 3.64M | -12.77M | 2.1M | -34.71M | 19.18M | -1.96M | 0 |
| Change in Receivables | 0 | -500K | 500K | -5.51M | -3.16M | -29.8M | 36.65M | -1.11M | 2.62M |
| Change in Inventory | 0 | -4.25M | -4.28M | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 2.51M | 4.25M | 4.28M | -1.55M | 0 | 14.25M | -28.94M | -1.66M | -9.03M |
| Cash from Investing | -10.2M | -463K | -157.45M | -161.08M | -324.02M | 166.75M | 112.67M | 12.22M | 111.17M |
| Capital Expenditures | -1.73M | -2.3M | -7.39M | -4.93M | -50.7M | -35.57M | -6.15M | -730K | -5.95M |
| CapEx % of Revenue | 42.01% | 48.59% | 69.24% | 15.69% | 90.79% | 36.93% | 9.68% | 5.36% | 89.57% |
| Acquisitions | 0 | 0 | 150.06M | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -8.47M | 1.84M | -150.06M | 0 | 0 | 0 | 0 | 0 | 362K |
| Cash from Financing | 47.44M | 140.78M | 149.93M | 282.84M | 453.13M | 9.21M | 85K | 99.89M | 5.49M |
| Debt Issued (Net) | 4.15M | 0 | -15M | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 85K | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 283K | 6.2M | 2.52M | 490K | 41.39M | 0 | 0 | 5.07M | 5.49M |
| Net Change in Cash | 343K▲ 0% | 101.67M▲ 29540.5% | -90.7M▼ 189.2% | 67.53M▲ 174.5% | -33.76M▼ 150.0% | -72.25M▼ 114.0% | -19.46M▲ 73.1% | -5.81M▲ 70.1% | 10.57M▲ 281.8% |
| Free Cash Flow | -38.63M▲ 0% | -40.95M▼ 6.0% | -90.57M▼ 121.2% | -44.16M▲ 51.2% | -213.57M▼ 383.6% | -283.77M▼ 32.9% | -138.42M▲ 51.2% | -123.6M▲ 10.7% | -112.04M▲ 9.4% |
| FCF Margin % | -940.82% | -863.99% | -848.03% | -140.49% | -382.43% | -294.68% | -217.86% | -906.79% | -1685.78% |
| FCF Growth % | -27.58% | -6.01% | -121.16% | 51.24% | -383.63% | -32.87% | 51.22% | 10.7% | 9.36% |
| FCF per Share | -0.92 | -0.73 | -1.33 | -0.54 | -2.25 | -2.93 | -1.41 | -1.09 | -0.94 |
| FCF Conversion (FCF/Net Income) | 0.86x | 0.58x | 0.85x | 0.23x | 0.77x | 0.88x | 0.82x | 0.66x | 0.78x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
FATE Key Ratios
Fate Therapeutics, Inc. (FATE) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -60.19% | -57.14% | -56.05% | -48.44% | -55.11% | -39.9% | -48.46% | -37.76% | -54.21% | -51.84% |
| Return on Invested Capital (ROIC) | - | -1037.56% | - | -96.42% | -39.51% | -33.4% | -38.81% | -29.7% | -39.52% | -36.54% |
| Gross Margin | -500.91% | -736.78% | -1081.94% | 100% | -299.64% | 89.52% | 85.71% | -147.41% | 100% | - |
| Net Margin | -760.15% | -1046.08% | -1405.02% | -919% | -551.59% | -379.89% | -292.55% | -253.3% | -1366.46% | -2051.08% |
| Debt / Equity | 0.15x | 0.19x | 0.09x | 0.11x | 0.25x | 0.17x | 0.23x | 0.28x | 0.27x | 0.38x |
| Interest Coverage | -19.53x | -33.22x | -39.56x | -57.49x | - | - | - | - | - | - |
| FCF Conversion | 0.89x | 0.86x | 0.58x | 0.85x | 0.23x | 0.77x | 0.88x | 0.82x | 0.66x | 0.78x |
| Revenue Growth | 81.08% | -6.72% | 15.44% | 125.32% | 194.33% | 77.66% | 72.44% | -34.03% | -78.55% | -51.24% |
FATE SEC Filings & Documents
Fate Therapeutics, Inc. (FATE) SEC filings — annual & quarterly reports (10-K, 10-Q)
FATE Frequently Asked Questions
Fate Therapeutics, Inc. (FATE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Fate Therapeutics, Inc. (FATE) reported $6.6M in revenue for fiscal year 2025. This represents a 468% increase from $1.2M in 2011.
Fate Therapeutics, Inc. (FATE) saw revenue decline by 51.2% over the past year.
Fate Therapeutics, Inc. (FATE) reported a net loss of $136.3M for fiscal year 2025.
Dividend & Returns
Fate Therapeutics, Inc. (FATE) has a return on equity (ROE) of -51.8%. Negative ROE indicates the company is unprofitable.
Fate Therapeutics, Inc. (FATE) had negative free cash flow of $87.5M in fiscal year 2025, likely due to heavy capital investments.
Explore More FATE
Fate Therapeutics, Inc. (FATE) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates